MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative
Kelsey R Thomas, Emily C Edmonds, Joel S Eppig, Christina G Wong, Alexandra J Weigand, Katherine J Bangen, Amy J Jak, Lisa Delano-Wood, Douglas R Galasko, David P Salmon, Steven D Edland, Mark W Bondi, Alzheimer's Disease Neuroimaging Initiative, Kelsey R Thomas, Emily C Edmonds, Joel S Eppig, Christina G Wong, Alexandra J Weigand, Katherine J Bangen, Amy J Jak, Lisa Delano-Wood, Douglas R Galasko, David P Salmon, Steven D Edland, Mark W Bondi, Alzheimer's Disease Neuroimaging Initiative
Abstract
Introduction: The low mild cognitive impairment (MCI) to cognitively normal (CN) reversion rate in the Alzheimer's Disease Neuroimaging Initiative (2-3%) suggests the need to examine reversion by other means. We applied comprehensive neuropsychological criteria (NP criteria) to determine the resulting MCI to CN reversion rate.
Methods: Participants with CN (n = 641) or MCI (n = 569) were classified at baseline and year 1 using NP criteria. Demographic, neuropsychological, and Alzheimer's disease biomarker variables as well as progression to dementia were examined across stable CN, reversion, and stable MCI groups.
Results: NP criteria produced a one-year reversion rate of 15.8%. Reverters had demographics, Alzheimer's disease biomarkers, and risk-of-progression most similar to the stable CN group and showed the most improvement on neuropsychological measures from baseline to year 1.
Discussion: NP criteria produced a reversion rate that is consistent with, albeit modestly improved from, reversion rates in meta-analyses. Reverters' biomarker profiles and progression rates suggest that NP criteria accurately tracked with underlying pathophysiologic status.
Keywords: Alzheimer's disease; Diagnostic criteria; Mild cognitive impairment; Neuropsychology; Reversion; Stability.
Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Figures
Source: PubMed